There’s been a sudden surge in consumer interest in metabolic health, driven by headlines about GLP-1 drugs. Google Trends data shows search volume for the term “metabolic health” quintupled over the past five years. As brands rethink their metabolic portfolios, clinically substantiated ingredients like Chromax® are coming into sharper focus.
The Metabolic Health Shift
GLP-1 drugs aren’t simple appetite suppressants. They work by altering people’s metabolic processes, slowing gastric emptying, increasing insulin secretion in response to glucose, reducing glucagon, improving glycemic control, and influencing satiety.1
The success of these drugs has increased consumer attention around the importance of metabolism to weight management. People who never thought about blood glucose are now talking about A1c, insulin resistance, and metabolic dysfunction. Perhaps the biggest shift is that the conversation around weight loss has shifted away from “willpower” and toward the broader subject of metabolic health.
Where Chromax® Shines
Supplements that appeal to consumers hoping to support their healthy weight maintenance goals and maintain muscle mass during a weight management program are quickly rising in popularity.2,3 Chromax® is one such ingredient that can support these needs. Supported by more than a dozen clinical studies, this highly bioavailable Chromium Picolinate aids with maintaining muscle mass or lean body mass during weight loss as part of a healthy diet and lifestyle, making it attractive to today’s metabolically aware consumer.*
A key advantage of Chromax® is its superior bioavailability; human clinical research shows it is absorbed up to 15X better than other forms of chromium.*4,5 As Chromax® is absorbed into the bloodstream, its unique structure promotes healthy insulin function.* By supporting how the cell responds to insulin, Chromax supplementation has been shown to support healthy blood sugar balance, carbohydrate metabolism, support with appetite and cravings, and maintain muscle mass during weight loss.*
The Science Behind Chromax®
Chromax® is the most clinically studied chromium picolinate ingredient on the market, supporting multiple aspects of metabolic health.*
Body composition
GLP-1s have raised concerns about the importance of body composition—the ratio of body fat to lean body mass—not just the numbers on a scale. Clinical research has revealed that a significant amount of weight lost by GLP-1 users is muscle, not fat. In fact, nearly 40% of the pounds shed in the STEP 1 trial came from lean mass.6
Long before body composition had entered the national conversation about weight management, research on Chromax® was already making the case for supporting healthy body composition by helping individuals to maintain their lean body mass during efforts to lose weight. In a 12-week, randomized, double-blind, placebo-controlled trial with 154 participants on weight loss programs of their choosing, Chromax® was found to promote healthy body composition by supporting individuals weight loss goals while importantly, maintaining their lean body mass.*
In a follow-up study by the same researchers, 122 participants took 400 mcg of Chromax® for 90 days alongside a healthy diet and lifestyle. Those in the Chromax® group lost significantly more weight (7.79 v. 1.81 kg) and fat mass (7.71 kg v. 1.53 kg) than those in the placebo group.* They also had a significantly greater reduction in body fat percentage (6.3% v. 1.2%)—with no loss of lean mass.*8
Cravings control & appetite management
Nagging hunger, as well as cravings for specific foods, have derailed many a diet. Chromax® has been shown to lend a helping hand in these areas as well. In a double-blind, randomized multicenter trial of 113 participants, those taking 600 mcg of Chromax® daily for 8 weeks experienced more than a 2x reduction in carbohydrate cravings and a 1.8x reduction in appetite versus placebo.*9
Another randomized, double-blind placebo-controlled trial tested the impact of Chromax® in modulating food intake among 42 overweight women. Compared to placebo, taking 1,000 mcg of Chromax® daily over 8 weeks significantly reduced caloric intake (by 350 calories versus 150 in the placebo group), hunger levels, and fat cravings.*10
Blood sugar & insulin function
A clinical study reported that chromium picolinate helped support healthy glucose metabolism and insulin function.*¹ Another independent trial found that this form of chromium supported a healthy metabolic response to carbohydrate intake, consistent with its well‑characterized bioavailability profile.*12
Why Brands Are Turning to Chromax®
Chromax® is a key ingredient in the evolving category of metabolic health, offering several advantages over other forms of chromium:
- Superior bioavailability: Up to 15 times higher than other forms of chromium
- Clinically researched: Backed by 17 human clinical studies
- USP grade: meets USP specifications for identity, strength, quality, and purity
- Versatile: Easily incorporated into tablets, capsules, powders, beverages, and bars
With its credibility and brand recognition, Chromax® is a perfect fit for modern metabolic formulas.
Conclusion
Metabolic health is now a mainstream health focus. Consumers understand the importance of well-regulated blood sugar and insulin as well as optimized body composition. Chromax® is a clinically grounded solution for brands formulating products in a modern GLP-1 landscape.
Discover more benefits and applications of Chromax by downloading our infographic.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
References
1. VCU Health. July 1, 2025. https://vcuhealth.org/news/what-do-glp-1-receptor-agonists-actually-do/
2. Dicker S, Chan E. SPINS. April 8, 2025. https://www.spins.com/resources/blog/active-nutrition-a-comprehensive-market-overview-and-emerging-trends/
3. Global Market Insights Inc. December 2024. https://www.gminsights.com/industry-analysis/creatine-supplement-market
4. Anderson RA, Polansky MM, Bryden NA. Biol Trace Elem Res. 2004;101(3):211-218. doi:10.1385/BTER:101:3:211
5. DiSilvestro RA, Dy E. J Trace Elem Med Biol. 2007;21(2):120-124. doi:10.1016/j.jtemb.2007.01.004
6. Wilding JPH, Batterham RL, Calanna S, et al. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183
7. Kaats GR, Blum K, Fisher JA, Adelman JA. Curr Ther Res. 1996;57(10):747-756. doi:10.1016/S0011-393X(96)80080-4
8. Kaats GR, Blum K, Pullin D, Keith SC, Wood R. Curr Ther Res. 1998;59(6):379-388. doi:10.1016/S0011-393X(98)85040-6
9. Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR. J Psychiatr Pract. 2005;11(5):302-314. doi:10.1097/00131746-200509000-00004
10. Anton SD, Morrison CD, Cefalu WT, et al. Diabetes Technol Ther. 2008;10(5):405-412. doi:10.1089/dia.2007.0292
11. Frauchiger MT, Zempleni J, McMahon RJ, et al. J Am Coll Nutr. 2004;23(4):351‑357. PMID:15310739
12. Cefalu WT, Bell-Farrow AD, Petty M, et al. J Trace Elem Exp Med. 1999;12(2):71‑83. doi:10.1002/(SICI)1520-670X(1999)12:2<71::AID-JTRA4>3.0.CO;2-8
